Survey of clinical practice and prognostic factors for unresectable locally advanced pancreatic cancer: Multicenter prospective observational study
Not Applicable
Recruiting
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000045799
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
Not provided
Exclusion Criteria
1. Your physician determines that you are unsuitable for enrollment in the study. 2. Contrast-enhanced CT imaging is not possible due to drug allergy to iodine-based contrast media. However, contrast-enhanced CT imaging is not possible with steroid prophylactic administration. 3. Pleural effusion and ascites for which metastasis cannot be ruled out are observed on chest CT and abdominal / pelvic contrast CT. 4. Contrast-enhanced MRI shows a liver mass that metastasis cannot be ruled out. 5. Active double cancer (simultaneous double cancer). However, lesions such as carcinoma in situ or intramucosal cancer that are judged to be cured by topical therapy are not included in active double cancer.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival
- Secondary Outcome Measures
Name Time Method